List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 51 studies with search of:   "Verteporfin"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
Condition: Macular Degeneration
Interventions: Drug: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab
2 Recruiting Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
Conditions: Age-Related Maculopathy;   Choroidal Neovascularization
Interventions: Drug: Ranibizumab;   Drug: Verteporfin;   Drug: Verteporfin
3 Active, not recruiting Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Interventions: Drug: verteporfin, ranibizumab;   Drug: verteporfin;   Drug: Ranibizumab
4 Active, not recruiting Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
Conditions: Age Related Macular Degeneration;   Choroidal Neovascularization;   Macular Edema
Interventions: Drug: Bevacizumab and verteporfin photodynamic therapy;   Drug: Bevacizumab and visudyne photodynamic therapy
5 Completed A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
Conditions: Macular Degeneration;   Choroidal Neovascularization
Interventions: Drug: Verteporfin and triamcinolone 1 mg;   Drug: Verteporfin and triamcinolone 4 mg;   Drug: Verteporfin and Pegaptanib
6 Active, not recruiting Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
Conditions: Choroidal Neovascularization;   Macular Degeneration
Interventions: Drug: verteporfin, ranibizumab;   Drug: verteporfin, ranibizumab, dexamethasone;   Drug: ranibizumab;   Drug: verteporfin, ranibizumab, dexamethasone
7 Terminated Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Interventions: Drug: Photodynamic Therapy (PDT) with Visudyne (verteporfin);   Drug: Macugen (pegaptanib sodium)
8 Completed Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)
Condition: Chronic Central Serous Chorioretinopathy
Interventions: Procedure: Photodynamic Therapy with Verteporfin;   Drug: verteporfin;   Drug: Verteporfin
9 Active, not recruiting Photodynamic and Pharmacologic Treatment of CNV
Conditions: Choroidal Neovascularization;   Macular Degeneration
Interventions: Drug: verteporfin (Visudyne);   Drug: ranibizumab (Lucentis)
10 Active, not recruiting Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
Conditions: Macular Degeneration;   Choroidal Neovascularization
Interventions: Drug: ranibizumab;   Drug: ranibizumab, verteporfin
11 Recruiting Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
Condition: Neovascular Age Related Macular Degeneration
Intervention: Drug: Ranibizumab; Verteporfin
12 Active, not recruiting Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
Conditions: Macular Degeneration;   Choroidal Neovascularization
Interventions: Drug: Verteporfin for injection, Ranibizumab injection;   Drug: ranibizumab
13 Terminated Two Studies to Determine If Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.
Conditions: Basal Cell Carcinoma;   Nevoid Basal Cell Carcinoma Syndrome;   Gorlin Syndrome
Intervention: Drug: verteporfin PDT
14 Completed Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
Conditions: Choroidal Neovascularization;   Macular Degeneration
Interventions: Drug: Verteporfin;   Drug: Bevacizumab
15 Recruiting Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-Based Retreatment
Condition: Age-Related Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: Ranibizumab plus Photodynamic therapy
16 Withdrawn The Avastin vs Visudyne for Neovascular AMD Study
Condition: Age-Related Macular Degeneration
Interventions: Drug: Bevacizumab (Avastin);   Drug: Verteporfin photodynamic therapy (PDT)
17 Recruiting Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Interventions: Drug: Ranibizumab (Lucentis);   Drug: Visudyne
18 Completed Visudyne® in Occult (VIO)
Condition: Macular Degeneration
Intervention: Drug: Visudyne for injection
19 Terminated Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
Condition: Macular Degeneration
Intervention: Device: Verteporfin Therapy/ Drug: Bevacizumab
20 Recruiting Ranibizumab vs PDT for Presumed Ocular Histoplasmosis
Condition: Presumed Ocular Histoplasmosis (POHS)
Interventions: Drug: ranibizumab;   Drug: verteporfin

Previous Page Studies Shown (1-20) Next (21-40)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services